BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26961140)

  • 41. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.
    Madhavan D; Zucknick M; Wallwiener M; Cuk K; Modugno C; Scharpff M; Schott S; Heil J; Turchinovich A; Yang R; Benner A; Riethdorf S; Trumpp A; Sohn C; Pantel K; Schneeweiss A; Burwinkel B
    Clin Cancer Res; 2012 Nov; 18(21):5972-82. PubMed ID: 22952344
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
    Lindsay CR; Le Moulec S; Billiot F; Loriot Y; Ngo-Camus M; Vielh P; Fizazi K; Massard C; Farace F
    BMC Cancer; 2016 Feb; 16():168. PubMed ID: 26923772
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients.
    Ning Y; Zhang W; Hanna DL; Yang D; Okazaki S; Berger MD; Miyamoto Y; Suenaga M; Schirripa M; El-Khoueiry A; Lenz HJ
    Pharmacogenomics J; 2018 Jan; 18(1):29-34. PubMed ID: 27503579
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma.
    Liu T; Li Y; Song J; Li B; Wang R; Huang T; Qin Y
    Cancer Control; 2024; 31():10732748241251562. PubMed ID: 38716503
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients.
    Payne RE; Wang F; Su N; Krell J; Zebrowski A; Yagüe E; Ma XJ; Luo Y; Coombes RC
    Br J Cancer; 2012 May; 106(11):1790-7. PubMed ID: 22538972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.
    Satelli A; Brownlee Z; Mitra A; Meng QH; Li S
    Clin Chem; 2015 Jan; 61(1):259-66. PubMed ID: 25336717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical significance of epithelial-mesenchymal transition typing of circulating tumour cells in colorectal cancer.
    Hou J; Guo C; Lyu G
    Colorectal Dis; 2020 May; 22(5):581-587. PubMed ID: 31868956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
    Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
    Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.
    Paoletti C; Muñiz MC; Thomas DG; Griffith KA; Kidwell KM; Tokudome N; Brown ME; Aung K; Miller MC; Blossom DL; Schott AF; Henry NL; Rae JM; Connelly MC; Chianese DA; Hayes DF
    Clin Cancer Res; 2015 Jun; 21(11):2487-98. PubMed ID: 25381338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial-mesenchymal transition.
    Yang J; Ma J; Jin Y; Cheng S; Huang S; Zhang N; Wang Y
    Sci Rep; 2021 Mar; 11(1):6540. PubMed ID: 33753862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
    Papadaki MA; Stoupis G; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    Mol Cancer Ther; 2019 Feb; 18(2):437-447. PubMed ID: 30401696
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
    Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status.
    Vilsmaier T; Heidegger HH; Schröder L; Trapp E; Zehni AZ; Rack B; Janni W; Mahner S; Weissenbacher T; Jeschke U; Mumm JN;
    Arch Gynecol Obstet; 2021 Jan; 303(1):217-230. PubMed ID: 32929618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
    Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M
    J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer.
    Kirwan CC; Descamps T; Castle J
    Clin Transl Oncol; 2020 Jun; 22(6):870-877. PubMed ID: 31473984
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer.
    D'Oronzo S; Lovero D; Palmirotta R; Stucci LS; Tucci M; Felici C; Cascardi E; Giardina C; Cafforio P; Silvestris F
    Sci Rep; 2019 Nov; 9(1):17276. PubMed ID: 31754145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phenotypic Heterogeneity and Metastasis of Breast Cancer Cells.
    Hapach LA; Carey SP; Schwager SC; Taufalele PV; Wang W; Mosier JA; Ortiz-Otero N; McArdle TJ; Goldblatt ZE; Lampi MC; Bordeleau F; Marshall JR; Richardson IM; Li J; King MR; Reinhart-King CA
    Cancer Res; 2021 Jul; 81(13):3649-3663. PubMed ID: 33975882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
    Giuliano M; Giordano A; Jackson S; Hess KR; De Giorgi U; Mego M; Handy BC; Ueno NT; Alvarez RH; De Laurentiis M; De Placido S; Valero V; Hortobagyi GN; Reuben JM; Cristofanilli M
    Breast Cancer Res; 2011 Jun; 13(3):R67. PubMed ID: 21699723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.